Products
Temafloxacin (Omniflox) was withdrawn from the market in 1992 a few months after its initial approval in the United States because of the potential for serious side effects.
Structure and properties
Temafloxacin (C21H18F3N3O3, Mr = 417.4 g/mol) structurally belongs to the fluoroquinolones.
Effects
Temafloxacin (ATC J01MA05) is bactericidal. Effects are due to inhibition of bacterial topoisomerase II (gyrase) and topoisomerase IV, which play a central role in bacterial proliferation.
Indications
For the treatment of bacterial infectious diseases.
Adverse effects
Severe possible adverse effects include hemolytic anemia, coagulopathy, and renal and hepatic dysfunction.
